Ultimately, any attempt at promoting a durable progression free survival period for patients with metastatic NSCLC, even if oligometastatic, usually would require the ability of the patient to tolerate some systemic therapy. Nearly all of the studies that have incorporated local therapies in the for...

I agree with @Puneeth Iyengar. The principal focus of using SBRT/local therapy for oligometastatic has come to bear more recently in an era with improved systemic therapy, and an understanding that the sites most likely to progress after an initial course of systemic therapy are the initial sites of...